DPP4 and heart failure: In contrast to DPP-4 inhibitors and GLP-1 agonists, the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin reduced the risk of heart failure in the CANVAS [29], DECLARE–TIMI [30], and EMPA-REG OUTCOME [31, 32] trials, respectively.